Deutsche Märkte öffnen in 54 Minuten

Smith & Nephew plc (SN.L)

LSE - LSE Verzögerter Preis. Währung in GBp (0.01 GBP)
Zur Watchlist hinzufügen
1.021,00-0,50 (-0,05%)
Börsenschluss: 04:45PM GMT

Smith & Nephew plc

Building 5
Croxley Park Hatters Lane
Watford WD18 8YE
United Kingdom
44 1923 477 100
https://www.smith-nephew.com

Sektor(en)Healthcare
BrancheMedical Devices
Vollzeitmitarbeiter19.000

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Deepak S. Nath Ph.D.CEO & Director4,71MN/A1972
Ms. Anne-Francoise NesmesCFO & Executive Director1,07MN/A1972
Mr. Paul ConnollyPresident of Global OperationsN/AN/A1968
Mr. Andrew SwiftVice President of Investor RelationsN/AN/AN/A
Ms. Helen BarracloughGroup General Counsel & Company SecretaryN/AN/A1980
Ms. Alison ParkesChief Compliance Officer & Compliance APACN/AN/A1973
Mr. Joe MetzgerSenior Vice President of Marketing Services & CommunicationsN/AN/AN/A
Mr. Philip G. CowdyChief Corporate Development & Corporate Affairs OfficerN/AN/A1967
Ms. Elga LohlerChief Human Resources OfficerN/AN/A1968
Mr. Bradley CannonPresident of Global OrthopaedicsN/AN/A1968
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in GBp.

Beschreibung

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Corporate Governance

Smith & Nephew plcs ISS Governance QualityScore, Stand 28. November 2023, lautet 4. Die grundlegenden Scores sind Audit: 8, Vorstand: 2, Shareholderrechte: 1, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.